Approaches to synthetic platelet analogs

Biomaterials

Volumn 34, Issue 2, 2013, Pages 526-541

  Modery Pawlowski, Christa L ^a   Tian, Lewis L ^a   Pan, Victor ^a   McCrae, Keith R ^b   Mitragotri, Samir ^c   Sen Gupta, Anirban ^a  

^a Case Western Reserve University   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c University of California   (United States)

Author keywords

Adhesion; Aggregation; Margination; Synthetic platelet

Indexed keywords

MARGINATION; MYELOSUPPRESSION; OPTIMUM DESIGNS; PATHOGEN REDUCTION; PHYSICOMECHANICAL PROPERTIES; PLATELET CONCENTRATES; PLATELET MEMBRANES; PLATELET TRANSFUSIONS; SHELF LIFE; SIDE EFFECT; SINGLE PARTICLE; SYNTHETIC ANALOGS;

ADHESION; AGGLOMERATION; ELASTICITY; PLATELETS;

BLOOD SUBSTITUTES;

FIBRINOGEN RECEPTOR; HEMOSTATIC AGENT; LIPOSOME; VON WILLEBRAND FACTOR;

BIOCOMPATIBILITY; CELL SHAPE; CELL SIZE; CONFORMATIONAL TRANSITION; DRUG DELIVERY SYSTEM; FREEZE DRYING; HEMODYNAMICS; HEMOSTASIS; HUMAN; HYDRODYNAMICS; IMMUNOGENICITY; LIGAND BINDING; MOLECULAR MIMICRY; MOLECULAR WEIGHT; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SHEAR RATE; SHELF LIFE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE MEMBRANE;

ANIMALS; ARTIFICIAL CELLS; BIOMIMETIC MATERIALS; BIOMIMETICS; BLOOD PLATELETS; HEMOSTASIS; HUMANS;

EID: 84868204706     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.09.074     Document Type: Review

References (135)

1. Mohanty D. Current concepts in platelet transfusion. Asian J Transfus Sci 2009, 3(1):18-21.
2. Lee D., Blajchman M.A. Novel treatment modalities: new platelet preparations and substitutes. Br J Haematol 2001, 114(3):496-505.
3. Furie B., Cassileth P. Clinical hematology and oncology: presentation, diagnosis, and treatment 2003, Churchill Livingstone, London.
4. American red cross blood facts and statistics 2012 Sept, Available from: URL:. http://www.redcrossblood.org/learn-about-blood/blood-facts-and-statistics.
5. The National blood collection and utilization survey report. 2012 Sept. Available from: URL: http://www.aabb.org/programs/biovigilance/nbcus/Pages/default.aspx.
6. Solheim B.G. Pathogen reduction of blood components. Transfus Apher Sci 2008, 39(1):75-82.
7. Seghatchian J., de Sousa G. Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006, 35(3):189-196.
8. Epstein J.S., Vostal J.G. FDA approach to evaluation of pathogen reduction technology. Transfusion 2003, 43:1347-1350.
9. Galan A.M., Lozano M., Molina P., Navalon F., Marschner S., Goodrich R., et al. Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function. Transfusion 2011, 51(4):808-815.
10. ®) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS. Vox Sang 2009, 97(3):234-239.
11. Slichter S.J. Platelet refractoriness and alloimmunization. Leukemia 1998, 12(Suppl. 1):S51-S53.
12. Novotný V.M., Doxiadis, Brand A. The reduction of HLA class I expression on platelets: a potential approach in the management of HLA-alloimmunized refractory patients. Transfus Med Rev 1999, 13(2):95-105.
13. Blajchman M.A. Immunomodulatory effects of allogeneic blood transfusions: clinical manifestations and mechanisms. Vox Sang 1998, 74(Suppl. 2):315-319.
14. Orlin J.B., Ellis M.H. Transfusion-associated graft-versus-host disease. Curr Opin Hematol 1997, 4(6):442-448.
15. Takeoka S. Design and modification of nanoparticles for blood substitutes. Organ Microcirc 2005, 13:35-41.
16. Kickler T.S. Alternatives to platelet transfusions in the management of platelet dysfunction or thrombocytopenia. TransAltern Trans Med 2006, 8(2):127-134.
17. Kresie L. Artificial blood: an update on current red cell and platelet substitutes. Proc (Bayl Univ Med Cent 2001, 14(2):158-161.
18. Blajchman M.A. Novel platelet products, substitutes and alternatives. Transfus Clin Biol 2001, 8(3):267-271.
19. Spencer F.A. Platelets: structure, function, and their fundamental contribution to hemostasis and pathologic thrombosis. Textbook of coronary thrombosis and thrombolysis: developments in cardiovascular medicine 1997, 31-49. Springer, New York. R.C. Becker (Ed.).
20. Frojmovic M.M., Milton J.G. Human platelet size, shape, and related functions in health and disease. Physiol Rev 1982, 62(1):185-261.
21. Canham P. The minimum energy of bending as a possible explanation of the bioconcave shape of the human red blood cell. J Theor Biol 1970, 26:61-81.
22. AlMomani T., Udaykumar H.S., Marshall J.S., Chandran K.B. Micro-scale dynamic simulation of erythrocyte-platelet interaction in blood flow. Ann Biomed Eng 2008, 36(6):905-920.
23. Haga J.H., Beaudoina J., White J.G., Strony J. Quantification of the passive mechanical properties of the resting platelet. Ann Biomed Eng 1998, 26(2):268-277.
24. Dulińska I., Targosz M., Strojny W., Lekka M., Czuba P., Balwierz W., et al. Stiffness of normal and pathological erythrocytes studied by means of atomic force microscopy. J Biochem Biophys Methods 2006, 66(1-3):1-11.
25. Radmacher M., Fritz M., Kacher C.M., Cleveland J.P., Hansma P.K. Measuring the viscoelastic properties of human platelets with the atomic force microscope. Biophys J 1996, 70(1):556-567.
26. Goldsmith H. Flow behavior of erythrocytes. II. Particle motions in concentrated suspensions of ghost cells. J Colloid Interface Sci 1979, 71(2):383-407.
27. Huang R.B., Mocherla S., Heslinga M.J., Charoenphol P., Eniola-Adefeso O. Dynamic and cellular interactions of nanoparticles in vascular-targeted drug delivery (review). Mol Membr Biol 2010, 27(4-6):190-205.
28. Aarts P., Heethaar R., Sixma J. Red blood cell deformability influences platelets-vessel wall interaction in flowing blood. Blood 1984, 64(64):1228-1233.
29. Burris S.M., Smith C.M., Tukey D.T., Clawson C.C., White J.G. Micropipette aspiration of human platelets after exposure to aggregating agents. Arteriosclerosis 1986, 6(3):321-325.
30. Kuwahara M. Platelet shape changes and adhesion under high shear flow. Arteriosclerosis 2002, 22(2):329-334.
31. Berndt M.C., Shen Y., Dopheide S.M., Gardiner E.E., Andrews R.K. The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost 2001, 86(1):178-188.
32. Ruggeri Z.M., Mendolicchio G.L. Adhesion mechanisms in platelet function. Circ Res 2007, 100(12):1673-1685.
33. Clemetson K.J., Clemetson J.M. Platelet collagen receptors. Thromb Haemost 2001, 86(1):189-197.
34. Nieswandt B., Watson S.P. Platelet-collagen interaction: is GPVI the central receptor?. Blood 2003, 102(2):449-461.
35. D'Souza S.E., Ginsberg M.H., Burke T., Plow E.F. The ligand binding site of the platelet integrin receptor GPIIb-IIIa is proximal to the second calcium binding domain of its alpha subunit. J Biol Chem 1990, 265(6):3440-3446.
36. Takeoka S., Teramura Y., Okamura Y., Tsuchida E., Handa M., Ikeda Y. Rolling properties of rGPIbalpha-conjugated phospholipid vesicles with different membrane flexibilities on vWf surface under flow conditions. Biochem Biophys Res Commun 2002, 296(3):765-770.
37. Takeoka S., Okamura Y., Teramura Y., Watanabe N., Suzuki H., Tsuchida E., et al. Function of fibrinogen gamma-chain dodecapeptide-conjugated latex beads under flow. Biochem Biophys Res Commun 2003, 312(3):773-779.
38. Okamura Y., Fujie T., Maruyama H., Handa M., Ikeda Y., Takeoka S. Prolonged hemostatic ability of polyethylene glycol-modified polymerized albumin particles carrying fibrinogen gamma-chain dodecapeptide. Transfusion 2007, 47(7):1254-1262.
39. Nishiya T., Kainoh M., Murata M., Handa M., Ikeda Y. Reconstitution of adhesive properties of human platelets in liposomes carrying both recombinant glycoproteins Ia/IIa and Ib alpha under flow conditions: specific synergy of receptor-ligand interactions. Blood 2002, 100(1):136-142.
40. Wada T., Okamura Y., Takeoka S., Sudo R., Ikeda Y., Tanishita K. Deformability and adhesive force of artificial platelets measured by atomic force microscopy. J Biorheol 2009, 23:35-40.
41. Nishiya T., Kainoh M., Murata M., Handa M., Ikeda Y. Platelet interactions with liposomes carrying recombinant platelet membrane glycoproteins or fibrinogen: approach to platelet substitutes. Artif Cells Blood Substit Immobil Biotechnol 2001, 29(6):453-464.
42. Ravikumar M., Modery C.L., Wong T.L., Sen Gupta A. Mimicking adhesive functionalities of blood platelets using ligand-decorated liposomes. Bioconjug Chem 2012, Epub Jun 5.
43. Nogami K., Shima M., Giddings J.C., Takeyama M., Tanaka I., Yoshioka A. Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain. Int J Hematol 2007, 85(4):317-322.
44. Rao G.H., Fields C.G., White J.G., Fields G.B. Promotion of human platelet adhesion and aggregation by a synthetic, triple-helical "mini-collagen". J Biol Chem 1994, 269(19):13899-13903.
45. Cejas M.A., Chen C., Kinney W.A., Maryanoff B.E. Nanoparticles that display short collagen-related peptides. Potent stimulation of human platelet aggregation by triple helical motifs. Bioconjug Chem 2007, 18(4):1025-1027.
46. Cejas M.A., Kinney W.A., Chen C., Vinter J.G., Almond H.R., Balss K.M., et al. Thrombogenic collagen-mimetic peptides: self-assembly of triple helix-based fibrils driven by hydrophobic interactions. Proc Natl Acad Sci USA 2008, 105(25):8513-8518.
47. Agam G., Livne A.A. Erythrocytes with covalently bound fibrinogen as a cellular replacement for the treatment of thrombocytopenia. Eur J Clin Invest 1992, 22:105-112.
48. Coller B.S., Springer K.T., Beer J.H., Mohandas N., Scudder L.E., Norton K.J., et al. Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions. J Clin Invest 1992, 89(2):546-555.
49. Gelderman M.P., Vostal J.G. Current and future cellular transfusion products. Clin Lab Med 2010, 30(2):443-452.
50. ProFibrix fibrocaps. 2012 Sept. Available from: URL: http://www.aabb.org/programs/biovigilance/nbcus/Pages/default.aspx.
51. Levi M., Friederich P.W., Middleton S., de Groot P.G., Wu Y.P., Harris R., et al. Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat Med 1999, 5(1):107-111.
52. Yen R.C., Ho T.W., Blajchman M.A. A new hemostatic agent: thrombospheres shorten the bleeding time (BT) in thrombocytopenic rabbits. Thromb Haemost 1995, 73:986.
53. Yen R.C.K., Ho T.W.C. A novel approach to correcting the bleeding associated with thrombocytopenia. Transfusion 1995, 35:41S.
54. Advanced therapeutics fibrinoplate 2012 Sept, Available from: URL:. http://www.advtx.com/Fibrinoplate-s-details.htm.
55. Bertram J.P., Williams C.A., Robinson R., Segal S.S., Flynn N.T., Lavik E.B. Intravenous hemostat: nanotechnology to halt bleeding. Sci Transl Med 2009, 1(11):11-22.
56. Hersel U., Dahmen C., Kessler H. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials 2003, 24(24):4385-4415.
57. Okamura Y., Takeoka S., Eto K., Maekawa I., Fujie T., Maruyama H., et al. Development of fibrinogen gamma-chain peptide-coated, adenosine diphosphate-encapsulated liposomes as a synthetic platelet substitute. J Thromb Haemost 2009, 7(3):470-477.
58. Okamura Y., Takeoka S., Teramura Y., Maruyama H., Tsuchida E., Handa M., et al. Hemostatic effects of fibrinogen gamma-chain dodecapeptide-conjugated polymerized albumin particles in vitro and in vivo. Transfusion 2005, 45(7):1221-1228.
59. Okamura Y., Fujie T., Nogawa M., Maruyama H., Handa M., Ikeda Y., et al. Haemostatic effects of polymerized albumin particles carrying fibrinogen gamma-chain dodecapeptide as platelet substitutes in severely thrombocytopenic rabbits. Transfus Med 2008, 18(3):158-166.
60. Okamura Y., Maekawa I., Teramura Y., Maruyama H., Handa M., Ikeda Y., et al. Hemostatic effects of phospholipid vesicles carrying fibrinogen gamma chain dodecapeptide in vitro and in vivo. Bioconjug Chem 2005, 16(6):1589-1596.
61. Cheng S., Craig W.S., Mullen D., Tschopp J.F., Dixon D., Pierschbacher M.D. Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists. J Med Chem 1994, 37(1):1-8.
62. Borzak S., Tisdale J.E., Amin N.B., Goldberg A.D., Frank D., Padhi I.D., et al. Atrial fibrillation after bypass surgery: does the arrhythmia or the characteristics of the patients prolong hospital stay?. Chest 1998, 113(6):1489-1491.
63. Ravikumar M., Modery C.L., Wong T.L., Sen Gupta A. Peptide-decorated liposomes promote arrest and aggregation of activated platelets under flow on vascular injury relevant protein surfaces in vitro. Biomacromolecules 2012, 13(5):1495-1502.
64. Ruggeri Z.M. Role of platelets in atherothrombosis. Nat Med 2002, 8(11):1227-1234.
65. Ruggeri Z.M. Platelet interactions with vessel wall components during thrombogenesis. Blood Cells Mol Dis 2006, 36(2):145-147.
66. Ruggeri Z.M., Dent J.A., Saldívar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 1999, 94(1):172-178.
67. Klein E., Farber S., Freman G. Effects of dried fraction from platelets on Ca clotting time of normal plasmas and plasma in thrombocytopenia and hemophilia. Fed Proc 1955, 14:410-1324.
68. Arnold P., Djerassi I., Ferber S., Freeman G., Klein E., Toch R. The preparation and clinical administration of lyophilized platelet material to children with acute leukemia and aplastic anemia. J Pediatr 1956, 49(5):517-522.
69. Klein E., Farber S., Djorassi I., Arnold P. Hemostasis following the administration of lyophilized platelet material in secondary thrombocytopenia. Sixth Intl Congr Hematol 1956, 525.
70. Fliedner D., Sorensen D., Bond V., Fliedner T. Comparing effectiveness of fresh and lyophilized platelets in controlling irradiation hemorrhage in the rat. Proc Soc Expl Biol 1958, 99:731-733.
71. Jackson D., Sorensen D., Cronkite E., Bond V., Fliedner T. Effectiveness of transfusions of fresh and lyophilized platelets in controlling bleeding due to thrombocytopenia. J Clin Invest 1959, 38:1689-1697.
72. Murphy M. An application of lyophilization and scanning electron microscopy. Thrombos Diath Haemorrh 1972, 28:237-243.
73. Allain J., Cooper H., Wagner R., Brinkhous K. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand Factor and platelet aggregating factor. J Lab Clin Med 1975, 85:328-335.
74. Brinkhous K.M., Read M.S. Preservation of platelet receptors for platelet aggregating factor/von Willebrand factor by air drying, freezing, or lyophilization: new stable platelet preparations for von Willebrand factor assays. Thromb Res 1978, 13(4):591-597.
75. Read M.S., Reddick R.L., Bode A.P., Bellinger D.A., Nichols T.C., Taylor K., et al. Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: potential for long-term storage of dried platelets for transfusion. Proc Natl Acad Sci USA 1995, 92(2):397-401.
76. Read M.S., Sanders W., Fischer T.H., Merricks E.P., Nichols T.C., Bode A.P., et al. Thrombus Formation with rehydrated, lyophilized platelets. Hematology 2002, 7:359-369.
77. Sanders W.E., Khandelwal G., Bellinger D.A., Bode A.P., Read M.S. Fibrinogen binding to rehydrated lyophilized platelet surface GPIIb-IIIa: normal clot formation and tPA lysis. Blood 1996, 88(Suppl. 1):30a.
78. Bode A.P. Preclinical testing of lyophilized platelets as a product for transfusion medicine. Transfus Sci 1995, 16(2):183-185.
79. Blajchman M.A., Lee D.H. The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes. Transfus Med Rev 1997, 11(2):95-105.
80. Bode A.P., Blajchman M.A., Bardossy L., Read M. Hemostatic properties of human lyophilized platelets in a thrombocytopenic rabbit model and a simulated bleeding time device. Blood 1994, 84(Suppl. 1):464a.
81. Woodman R.C., Harker L.A. Bleeding complications associated with cardiopulmonary bypass. Blood 1990, 76(9):1680-1697.
82. Bode A.P., Lust R.M., Read M.S., Fischer T.H. Correction of the bleeding time with lyophilized platelet infusions in dogs on cardiopulmonary bypass. Clin Appl Thromb Hemost 2008, 14(1):38-54.
83. Bode A.P., Read M., Summaria L., Lust R. Lyophilized platelets: nearing clinical trials. Platelets 1997, 8:436-437.
84. Bode A.P., Read M. Lyophilized platelets for transfusion medicine. Platelet therapy: current status and future challenges 2000, 131-167. Elsevier, Amsterdam. J. Seghatchan, E.L. Snyder (Eds.).
85. Hillyer C.D., Silberstein L.E., Anderson K.C., Ness P.M., Robak J.D. Blood banking and transfusion medicine: basic principles and practice 2007, Elsevier, Amsterdam, p. 328-30.
86. Pietramaggiori G., Kaipainen A., Ho D., Orser C., Pebley W., Rudolph A., et al. Trehalose lyophilized platelets for wound healing. Wound Repair Regen 2006, 15(2):213-220.
87. Nasiri S., Khosroshahi B.N. Lyophilization of human platelet and study of its aggregability. Int J Drug Del 2011, 3:241-244.
88. Bode A.P., Fischer T.H. Lyophilized platelets: fifty years in the making. Artif Cells Blood Substit Immobil Biotechnol 2007, 35(1):125-133.
89. Ahmadzadeh N., Yari F., Amirizadeh N., Khorramizadeh M.R. Production and characterization of liquid-stored and lyophilized reconstituted human infusible platelet membranes. Int J Lab Hematol 2011, 33(6):586-592.
90. Graham S.S., Gonchoroff N.J., Miller J.L. Infusible platelet membranes retain partial functionality of the platelet GPIb/IX/V receptor complex. Am J Clin Pathol 2001, 115(1):144-147.
91. Galan A.-M., Bozzo J., Pino M., Reverter J., Mazzara R., Ordinas A. Infusible platelet membranes improve hemostasis in thrombocytopenic blood: experimental studies under flow conditions. Transfusion 2000, 40:1074-1080.
92. Alving B.M., Reid T.J., Fratantoni J.C., Finlayson J.S. Frozen platelets and platelet substitutes in transfusion medicine. Transfusion 1997, 37(8):866-876.
93. Rybak M.E., Renzulli L.A. A liposome based platelet substitute, the plateletsome, with hemostatic efficacy. Biomater Artif Cells Immobilization Biotechnol 1993, 21(2):101-118.
94. Rybak M.E. A platelet substitute-the plateletsome to be used in transfusion therapy. Report by university of massachusetts medical center 1989, 1-41. US Army Medical Research and Development Command, Fort Detrick, Frederick, Maryland, Contract No. DAMD17-87-C-7172.
95. Okamura Y., Handa M., Suzuki H., Ikeda Y., Takeoka S. New strategy of platelet substitutes for enhancing platelet aggregation at high shear rates: cooperative effects of a mixed system of fibrinogen gamma-chain dodecapeptide- or glycoprotein Ibalpha-conjugated latex beads under flow conditions. J Artif Organs 2006, 9(4):251-258.
96. Charoenphol P., Huang R.B., Eniola-Adefeso O. Potential role of size and hemodynamics in the efficacy of vascular-targeted spherical drug carriers. Biomaterials 2010, 31(6):1392-1402.
97. Fujita H, Tsuji T, Tabata T, Takeoka S, Ikeda Y, Tanishita K. Motion of artificial platelet in the model arteriole. Proceedings of summer bioengineering conference. Key Biscayne, Florida. 2003: p. 29-30.
98. Gentile F., Chiappini C., Fine D., Bhavane R.C., Peluccio M.S., Cheng M.M.-C., et al. The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. J Biomech 2008, 41(10):2312-2318.
99. Toy R., Hayden E., Shoup C., Baskaran H., Karathanasis E. The effects of particle size, density and shape on margination of nanoparticles in microcirculation. Nanotechnology 2011, 22(11):1-9.
100. Decuzzi P., Lee S., Bhushan B., Ferrari M. A theoretical model for the margination of particles within blood vessels. Ann Biomed Eng 2005, 33(2):179-190.
101. Tao L., Hu W., Liu Y., Huang G., Sumer B.D., Gao J. Shape-specific polymeric nanomedicine: emerging opportunities and challenges. Exp Biol Med 2011, 236(1):20-29.
102. Pillai J.D., Dunn S.S., Napier M.E., DeSimone J.M. Novel platforms for vascular carriers with controlled geometry. IUBMB Life 2011, 63(8):596-606.
103. Doshi N., Prabhakarpandian B., Rea-Ramsey A., Pant K., Sundaram S., Mitragotri S. Flow and adhesion of drug carriers in blood vessels depend on their shape: a study using model synthetic microvascular networks. J Control Release 2010, 146(2):196-200.
104. Born G. Observations on the change in shape of blood platelets brought about by adenosine diphosphate. J Physiol 1970, 209:487-511.
105. Jeong W., Napier M.E., DeSimone J.M. Challenging nature's monopoly on the creation of well-defined nanoparticles. Nanomedicine 2010, 5(4):633-639.
106. Caldorera-Moore M., Kang M.K., Moore Z., Singh V., Sreenivasan S.V., Shi L., et al. Swelling behavior of nanoscale, shape- and size-specific, hydrogel particles fabricated using imprint lithography. Soft Matter 2011, 7(6):2879-2887.
107. Caldorera-Moore M., Guimard N., Shi L., Roy K. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv 2010, 7(4):479-495.
108. Mitragotri S., Lahann J. Physical approaches to biomaterial design. Nat Mater 2009, 8(1):15-23.
109. Champion J.A., Katare Y.K., Mitragotri S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release 2007, 121(1-2):3-9.
110. Champion J.A., Katare Y.K., Mitragotri S. Making polymeric micro- and nanoparticles of complex shapes. Proc Natl Acad Sci USA 2007, 104(29):11901-11904.
111. Merkel T.J., Jones S.W., Herlihy K.P., Kersey F.R., Shields A.R., Napier M., et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc Natl Acad Sci USA 2011, 108(2):586-591.
112. Doshi N., Orje J.N., Molins B., Smith J.W., Mitragorti S., Ruggeri Z.M. Platelet mimetic particles for targeting thrombi in flowing blood. Adv Mater 2012, 24(28):3864-3869.
113. US clinical trials 2012 Sept, Available from: URL:. http://www.clinicaltrials.gov.
114. Z-Medica QuikClot 2012 Sept, Available from: URL:. http://www.z-medica.com/healthcare/How-QuikClot-Works/How-QuikClot-Works.aspx.
115. Hedner U. Recombinant Factor Vlla (NovoSeven) as a hemostatic agent. Semin Hematol 2001, 38(4 Suppl. 12):43-47.
116. Novo Nordisk Inc NovoSeven. 2012 Sept. Available from: URL: http://www.novosevenrt.com/.
117. Erhardtsen E. Ongoing NovoSeven trials. Intensive Care Med 2002, 28(Suppl. 2):S248-S255.
118. CSL Behring LLC RioSTAP 2012 Sept, Available from: URL:. http://www.riastap.com/professional/default.aspx.
119. CSL Behring LLC BioState 2012 Sept, Available from: URL:. http://www.csl.com.au/s1/cs/auhq/1199978997194/Web_Product_C/1196562715720/ProductDetail.htm.
120. Amgen NPlate 2012 Sept, Available from: URL:. http://www.nplate.com/patient/how-nplate-may-help/index.html%3fWT.srch%3d1.
121. FDA draft guidance for industry for platelet testing and evaluation of platelet substitute products 2012 Sept, Available from: URL:, p. 123. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm077077.htm.
122. Brand A., Novotny V., Tomson B. Platelet transfusion therapy: from 1973 to 2005. Hum Immunol 2006, 67:413-418.
123. Pavenski K., Freedman J., Semple J. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens 2012, 78:237-245.
124. Hod E., Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008, 142:348-360.
125. Morrell C. Immunomodulatory mediators in platelet transfusion reactions. Hematol Am Soc Hematol Educ Program 2011, 470-474.
126. Sillliman C., Ambruso D., Boshkov L. Transfusion-related actute lung injury. Blood 2005, 105:2266-2273.
127. Stroncek D., Rebulla P. Transfusion medicine. Lancet 2007, 370:427-438.
128. Zolnik B., Gonzalez-Fernandez A., Sadrieh N., Dobrovolskaia M. Minireview: nanoparticles and the immune system. Endocrinology 2010, 151:458-465.
129. Zhang L., Gu F., Chan J., Wang A., Langer R., Farokhzad O. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008, 83(5):761-769.
130. Yoo J.-W., Chambers E., Mitragotri S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr Pharm Des 2010, 16(21):2298-2307.
131. Yu M., Park J., Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2012, 2(1):3-44.
132. Petrenko V. Evolution of phage display: from bioactive peptides to bioselective nanomaterials. Expert Opin Drug Deliv 2008, 5(8):1-12.
133. Okamura Y., Katsuno S., Suzuki H., Maruyama H., Handa M., Ikeda Y., et al. Release abilities of adenosine diphosphate from phospholipid vesicles with different membrane properties and their hemostatic effects as a platelet substitute. J Control Release 2010, 148(3):373-379.
134. Kona S., Dong J.-F., Liu Y., Tan J., Nguyen K.T. Biodegradable nanoparticles mimicking platelet binding as a targeted and controlled drug delivery system. Int J Pharm 2012, 423(2):516-524.
135. Korin N., Kanapathipillai M., Matthews B., Crescente M., Brill A., Mammoto T., et al. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science 2012, 337:738-742.